Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03218384 · ClinicalTrials.gov registry record · Phase 2
Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03218384 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 20 participants.
The verdict
NCT03218384, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand how body levels of iron affect the ability to exercise in patients with heart failure (HF). Heart failure is a condition in which abnormal pumping action of the heart reduces the flow of blood to the body. Patients with heart failure may feel shortness of breath or leg fatigue when they exercise. Iron is an essential nutrient in the diet. In heart failure patients, low body levels of iron might increase shortness of breath and fatigue.
Interventions
- DRUG Placebo
- DRUG Ferric Carboxymaltose
- DEVICE 31P MRS/MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-09-07 |
| Est. Completion | 2022-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03218384
The ClinicalTrials.gov registry entry for NCT03218384 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03218384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03218384 about?
NCT03218384 is a clinical study titled "Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency". The purpose of this study is to better understand how body levels of iron affect the ability to exercise in patients with heart failure (HF). Heart failure is a condition in which abnormal pumping action of the heart reduces the flow of blood to the body. Patients with heart failure may feel shortn...
What is the current status of trial NCT03218384?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-09-07. Estimated completion is 2022-04-04.
What interventions are being tested in trial NCT03218384?
The interventions under investigation include: Placebo (DRUG), Ferric Carboxymaltose (DRUG), 31P MRS/MRI (DEVICE).
Who is sponsoring clinical trial NCT03218384?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.